LEADER 03603nam  2200685 a 450 
001 9910778139003321
005 20230721022443.0
010   $a0-309-14109-5
010   $a1-282-23924-4
010   $a9786612239243
010   $a0-309-13040-9
035   $a(CKB)1000000000787845
035   $a(EBL)3378500
035   $a(SSID)ssj0000200515
035   $a(PQKBManifestationID)11220485
035   $a(PQKBTitleCode)TC0000200515
035   $a(PQKBWorkID)10220290
035   $a(PQKB)10335407
035   $a(MiAaPQ)EBC3378500
035   $a(Au-PeEL)EBL3378500
035   $a(CaPaEBR)ebr10315882
035   $a(CaONFJC)MIL223924
035   $a(OCoLC)923280394
035   $a(EXLCZ)991000000000787845
100   $a20091008d2009      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aMedical isotope production without highly enriched uranium$b[electronic resource] /$fCommittee on Medical Isotope Production Without Highly Enriched Uranium, Nuclear and Radiation Studies Board, Division of Earth and Life Studies, National Research Council of the National Academies
210   $aWashington, D.C. $cNational Academies Press$d2009
215   $a1 online resource (221 p.)
300   $aDescription based upon print version of record.
311   $a0-309-13039-5 
320   $aIncludes bibliographical references (p. 163-167).
327   $a""Preface""; ""Acknowledgments""; ""Reviewers""; ""Contents""; ""Summary""; ""1 Background and Study Task""; ""2 Molybdenum-99/Technetium-99m Production and Use""; ""3 Molybdenum-99/Technetium-99m Supply""; ""4 Molybdenum-99/Technetium-99m Supply Reliability""; ""5 Molybdenum-99/Technetium-99m Demand""; ""6 Molybdenum-99/Technetium-99m Production Costs""; ""7 Conversion to LEU-Based Production of Molybdenum-99: Technical Considerations""; ""8 Conversion to LEU-Based Production of Molybdenum-99: Regulatory Considerations""
327   $a""9 Conversion to LEU-Based Production of Molybdenum-99: General Approaches and Timing""""10 Conversion to LEU-Based Production of Molybdenum-99: Prospects and Feasibility""; ""11 Progress in Eliminating HEU Use""; ""References""; ""Appendix A: Section 630 of the Energy Policy Act of 2005""; ""Appendix B: Biographical Sketches of Committee Members""; ""Appendix C: Presentations and Visits""; ""Appendix D: Alternative Molybdenum-99 Production Processes""; ""Appendix E: Correspondence with Atomic Energy of Canada Limited""; ""Appendix F: Present Value Calculation""; ""Appendix G: Glossary""
327   $a""Appendix H: Acronyms""
606   $aUranium$xIsotopes$xTherapeutic use
606   $aHighly enriched uranium$xIsotopes$xTherapeutic use
606   $aMolybdenum$xIsotopes$xTherapeutic use
606   $aTechnetium$xIsotopes$xTherapeutic use
606   $aRadioisotopes$xTherapeutic use
606   $aNuclear medicine$xStandards$zUnited States
615  0$aUranium$xIsotopes$xTherapeutic use.
615  0$aHighly enriched uranium$xIsotopes$xTherapeutic use.
615  0$aMolybdenum$xIsotopes$xTherapeutic use.
615  0$aTechnetium$xIsotopes$xTherapeutic use.
615  0$aRadioisotopes$xTherapeutic use.
615  0$aNuclear medicine$xStandards
676   $a546.431
712 02$aNational Research Council (U.S.).$bNuclear and Radiation Studies Board.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910778139003321
996   $aMedical isotope production without highly enriched uranium$93738583
997   $aUNINA